A study to evaluate the effect of hepatic insufficiency on the pharmacokinetics (PK) of ACP-196

Study identifier:ACE-HI-001

ClinicalTrials.gov identifier:NCT04867941

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 2-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of ACP-196

Medical condition

Hepatic insufficiency

Phase

Phase 1

Healthy volunteers

Yes

Study drug

ACP-196

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 21 Oct 2014

Primary Completion Date: 02 Feb 2015

Study Completion Date: 02 Feb 2015

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2021 by Acerta Pharma BV

Collaborators

Inclusion and exclusion criteria

Inclusion Criteria

All Participants:
- Continuous non-smokers or smokers (of fewer than 20 cigarettes/day or the equivalent). Participants must agree to consume no more than 10 cigarettes or equivalent/day from
24 hours before dosing and throughout the period of sample collection.
- Women participants must be of non-child bearing status and must have negative serum pregnancy test.
- Men of reproductible potential must be willing to abstain from heterosexual intercourse or refrain from sperm donation or use contraception during the study and through 90 days after the last dose of study drug.
Hepatic impaired participants:
- Body mass index (BMI) >= 19 and <= 40 kg/m^2, at screening.
- Have medical history, physical examination, vital signs, 12-lead ECGs, and laboratory safety tests consistent with a diagnosis of hepatic impairment, but is otherwise judged to be in good health as determined by the principal investigator (PI).
- Participant has a diagnosis of chronic (> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic
insufficiency with features of cirrhosis due to any etiology.
- Part 1 only: Mild - Participant’s score on the Child-Pugh scale must range from 5 to 6 (mild hepatic insufficiency) at screening. Moderate - Participant’s score on the Child-Pugh scale must range from 7 to 9 (moderate hepatic insufficiency) at screening. For participants who have compensated hepatic insufficiency while on medical therapy, they should be classified by their pretreatment parameters.
- Part 2 only: Severe - Participant’s score on the Child-Pugh scale must range from 10 to 15 (severe hepatic insufficiency) at screening. For participant's who have compensated hepatic insufficiency while on medical therapy, they should be classified by their pretreatment parameters.
Healthy control participants only:
- BMI >= 19 and <= 40 kg/m^2 at screening.
- Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or ECGs, as deemed by the PI. Liver function tests, and serum bilirubin, must be <= the upper limit of normal at screening.

Exclusion Criteria

All participants:
- History or presence of clinically significant or unstable medical or psychiatric condition or disease in the opinion of the PI.
- Participant is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
- Any clinically significant condition that may affect ACP-196 absorption in the opinion of the PI, including gastric restrictions and bariatric surgery (eg, gastric bypass).
- Unable to refrain from or anticipates use of medicines defined in the protocol..
- Have been on a diet incompatible with the on-study diet, in the opinion of the PI, within the 28 days before the dose of study drug, and throughout the study.
Hepatic impaired participants only:
- History or presence of drug abuse within the past 2 years before screening.
- Positive results for the urine or breathalyzer alcohol test and/or urine drug screen at screening or check-in, unless the positive drug screen is due to prescription drug use
and is approved by the PI and Acerta Pharma’s medical monitor.
- Known history of HIV or hepatitis B virus (HBV) or active infection with hepatitis C virus (HCV). During screening, participants who have active HCV infection or
unstable levels of transaminase consistent with active Hepatitis C, will be excluded.
- No hepatic impaired participant will be dosed in both Part 1 and Part 2.
Healthy control participants only:
- History or presence of clinically significant thyroid disease, in the opinion of the PI.
- History or presence of alcoholism and/or drug abuse within the past 2 years before screening.
- Positive results for the urine or breathalyzer alcohol test and/or urine drug screen at screening.
- Positive results at screening for hepatitis B surface antigen or HCV.
- Seated blood pressure is less than 90/40 mmHg or greater than 150/95 mmHg at screening.
- Seated heart rate is lower than 40 beats per minute (bpm) or higher than 99 bpm at screening.
- Hemoglobin level below the lower limit of normal at screening, and considered clinically significant by the PI.

No locations available

Arms	Assigned Interventions
Experimental: Part1: Mild hepatic insufficiency Participants with mild hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.	Drug: ACP-196 All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study. Other Name: Acalabrutinib
Experimental: Part 1: Moderate hepatic insufficiency Participants with moderate hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.	Drug: ACP-196 All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study. Other Name: Acalabrutinib
Experimental: Part 1: Normal hepatic function Participants with normal hepatic function will receive a single oral dose of 50 mgACP-196 (2 x 25 mg capsules) on Day 1 of the study.	Drug: ACP-196 All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study. Other Name: Acalabrutinib
Experimental: Part 2: Severe hepatic insufficiency Participants with sever hepatic insufficiency will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.	Drug: ACP-196 All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study. Other Name: Acalabrutinib

Documents available

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=ACE-HI-001&attachmentIdentifier=07bd6393-67f8-4489-8607-2b70f8a36244&fileName=ACE-HI-001-_Study_Synopsis_-_CSR-redacted.pdf&versionIdentifier=
Download
Trial Results Summaries
Available here

Contacts

Contact

Priti Patel

+1 (650) 591-2800

Investigators

Principal Investigator